Making it in Manufacturing

ARTO Talent
  • 0.0 (0)
  • Karriere
  • Wöchentlich

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

  1. If You're Not Using AI in Validation Yet, You're Already Behind - Bruce Klopfenstein

    vor 5 Tagen

    If You're Not Using AI in Validation Yet, You're Already Behind - Bruce Klopfenstein

    95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes. What does it actually take to deliver a pharmaceutical facility project without it going off the rails? This week, Thomas McMann sat down with someone who has spent over 30 years doing exactly that, from both sides of the table. This week on Making It In Manufacturing, Thomas McMann sat down with Bruce Klopfenstein, Project Manager at GSK, with over 30 years of experience spanning project management, engineering, validation, EPC consulting, and client-side leadership across companies including GSK, Jacobs, JohnsonAndJohnson, Fujifilm and IBM. In this episode, Bruce covers: - Why getting ACV engaged at the very start of a project changes everything, and why the industry has been slow to do it. - Who is actually responsible when a pharmaceutical project goes over budget, and why change control is almost always at the root of it. - The $100,000 mistake that came down to a missing piece of paper, and the engineer who had to fly to Europe during Covid to fix it. - How GSK is leading a major sustainability push through its low-carbon inhaler propellant project in France, and why 49% of their total annual emissions trace back to a single product type. - Why AI adoption in pharmaceutical validation is no longer optional, and how companies like GSK and Eli Lilly are already using it inside the firewall, with Bruce's take on ValKit AI and what large language models can do for protocol generation at scale. This is a genuinely experienced perspective on what it takes to manage complex pharmaceutical projects, and what the industry needs to do differently. Worth your time whether you are on the EPC side, the client side, or deep in the validation world. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent LinkedIn Bruce Klopfenstein LinkedIn: https://www.linkedin.com/in/bruceklopfenstein/ Thomas McMann LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 0:00 Introduction 1:40 Bruce's ISP talk: early ACV engagement from Basis of Design through Detailed Design 3:13 Bruce's career journey: IBM, PricewaterhouseCoopers, gaming industry, J&J, and life science 8:09 Finding the most enjoyable moments: it is about the team and the situation, not just the job 13:13 Engineering complexity of the 152A propellant transition and where the project currently stands 16:33 The CO2 comparison between pharma and automotive: why the headline is misleading 19:54 Who is responsible when a project goes over budget? EPC vs client-side accountability 23:08 The biggest differences between working on the EPC side vs the client side 25:20 Why relationships are the foundation of every successful project 30:10 EPC stress vs owner stress: where the real pressure sits 36:18 Why pharma struggles to standardise the way oil and gas has 40:04 Change control in practice: what it actually requires 43:07 Equipment lead times and Covid-era supply chain pressure on the critical path 45:44 AI in pharmaceutical validation: where the industry is today 46:26 ValKit AI and Hugh Devine: using LLMs to generate validation protocols 47:18 The FDA's first AI warning letter and what it means for human oversight 53:31 How to think about AI like a smart intern: natural language, not programming 55:38 Why companies that are not adopting AI now will fall behind 56:00 Closing thoughts and sign-off #MakingItInManufacturing #ARTOTalent #ProjectManagement #Validation #LifeSciences #Biotech #AIInPharma #Commissioning #GMP #DrugManufacturing #Sustainability #GSK #EPC Hosted on Acast. See acast.com/privacy for more information.

    57 Min.
  2. Why Fujifilm Biotechnologies Thinks the CDMO Model Is Broken

    10. Juni

    Why Fujifilm Biotechnologies Thinks the CDMO Model Is Broken

    What does it take to transform a biologics manufacturing business into a global CDMO leader while keeping culture, transparency and patient impact at the centre of every decision? This week on Making It In Manufacturing, Thomas McMann sat down with Lars Petersen, CEO of Fujifilm Biotechnologies, with more than 30 years of experience spanning biologics manufacturing, engineering, operations leadership, global site leadership and biotech innovation across Novo Nordisk, Genentech, Roche and Biogen. In this episode, Lars covers: • Why “Partners for Life” became the foundation of Fujifilm Biotechnologies’ long-term customer strategy and how transparency reshaped CDMO partnerships • How personal loss, engineering curiosity and early leadership experiences at Novo Nordisk shaped Lars’ approach to people, manufacturing and patient impact • Lessons from the California biotech ecosystem at Genentech and Roche, including how culture and scientific purpose influenced leadership philosophy • How the KojoX modular manufacturing platform is helping reduce engineering timelines, improve scalability and rethink biologics facility design • Why AI will transform pharmaceutical manufacturing and how Fujifilm Biotechnologies is preparing the next evolution of biologics production Lars shares an honest perspective on leadership, scaling culture globally, operational excellence and the future of biologics manufacturing. For anyone working across biotech, pharma manufacturing, CDMOs or advanced therapies, this conversation offers a rare look into the mindset behind one of the industry’s fastest-growing organisations. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Lars Petersen LinkedIn: https://www.linkedin.com/in/lars-petersen-5134362/ Thomas McMann LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 02:14 Introduction to Lars Petersen and Fujifilm Biotechnologies 03:09 The meaning behind “Partners for Life” 06:35 Growth of Fujifilm and the secrets behind its success 07:26 How CDMOs are becoming strategic partners for pharma 08:41 Lars' journey into pharmaceuticals and personal motivation 10:47 Did Lars always want to become a CEO? 12:12 Engineering mindset vs. people leadership 13:55 Advantages of a technical background as a CEO 16:27 Lessons from 16 years at Novo Nordisk 19:15 Leaving comfort zones: moving to China and the United States 21:33 California, Genentech, and biotech culture 24:39 Lessons from Genentech and Roche 27:13 Leading the Biogen site acquisition by Fujifilm 32:03 Winning the first customer and validating the vision 34:11 The vision to become the “TSMC of biotech” 36:19 KojoX: Fujifilm's modular manufacturing platform 41:43 Defining a People-First culture 45:57 Maintaining culture while scaling globally 48:37 Self-awareness and leadership development 53:39 AI in biomanufacturing and the future of KojoX 55:10 What still motivates Lars after 30+ years in biotech 56:18 David Bowie, legacy, and final reflections 56:39 Closing remarks #MakingItInManufacturing #ARTOTalent #Biotech #PharmaceuticalManufacturing #CDMO #Biologics #AdvancedTherapies #CellTherapy #GeneTherapy #LifeSciences #ManufacturingLeadership Hosted on Acast. See acast.com/privacy for more information.

    55 Min.
  3. Inside CPHI Americas 2026: The Biggest Challenges Facing Pharma Right Now

    2. Juni

    Inside CPHI Americas 2026: The Biggest Challenges Facing Pharma Right Now

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. This week on Making It In Manufacturing, Thomas McMann sat down with Sarah Griffin, Event Manager for CPHI Americas. In this episode, Sarah covers: • Why CPHI Americas is creating a more focused, content-led experience built around meaningful industry conversations and strategic partnerships. • How the event has evolved to meet growing demand for deeper engagement between pharmaceutical companies, CDMOs, technology providers, regulators, and investors. • Why CDMOs are moving from outsourced service providers to long-term strategic partners, with greater transparency, collaboration, and shared risk. • How pharmaceutical companies are balancing supply chain resilience, regionalisation, outsourcing strategies, and operational agility in a changing global market. • What will define the next phase of growth for pharmaceutical services, including advanced therapies, AI integration, talent development, and partnership-driven business models. Be sure to watch this episode if you're attending CPHI Americas to get a complete overview of the agenda and key highlights. Even if you won't be there in person, it's still worth tuning in to stay up to date with the latest CPHI news, announcements, and live event updates. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Sarah Griffin LinkedIn: https://www.linkedin.com/in/sarah-griffin-cem/ Thomas McMann LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:00 Introduction 00:48 What makes CPHI Americas different 02:20 Why the event is becoming more content-led 03:25 New features and event changes for this year 04:31 The purpose behind the Hot Seat sessions 05:28 Sarah’s outlook ahead of the event 05:54 How CDMO partnerships are evolving 07:53 Supply chain resilience and outsourcing strategies 09:08 Demand for integrated pharmaceutical services 10:18 What separates successful CDMOs from competitors 12:03 Future growth drivers in pharmaceutical services 13:16 Collaboration and raising industry standards 14:11 What Sarah is most excited about at CPHI Americas 15:23 Sessions Sarah is looking forward to attending 16:23 Quick fire round 16:42 Biggest trend dominating pharma conversations 16:58 Biggest concern for pharma leaders 17:12 What makes CPHI Americas different from other events 17:37 Industry conversations that need more openness 18:09 Closing thoughts #MakingItInManufacturing #ARTOTalent #PharmaceuticalManufacturing #CDMO #PharmaServices #Biologics #CellAndGeneTherapy #SupplyChain #PharmaIndustry #DrugDevelopment Hosted on Acast. See acast.com/privacy for more information.

    19 Min.
  4. Why End-to-End CDMOs Matter More Than Ever - SmaBio Labs CEO

    21. Mai

    Why End-to-End CDMOs Matter More Than Ever - SmaBio Labs CEO

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. What does it take to build a CDMO designed around speed, integration, and true scientific collaboration? This week on Making It In Manufacturing, Harry Sloan sat down with LakshmiDevi Ethirajan, Co-Founder & CEO of SmaBioLabs, with 25+ years of experience spanning big pharma, small pharma, and CDMO leadership roles across drug development and manufacturing. In this episode, LakshmiDevi Ethirajan covers: • How a background in pharmacy and pharmaceutical development led to the creation of SmaBioLabs and the vision behind building a fully integrated CDMO • Why bringing discovery, formulation development, and analytical services together under one roof reduces risk and improves program execution • The importance of speed and flexibility in pharmaceutical development, including why projects at SmaBioLabs begin within two weeks of contract signing • How technical integration between discovery scientists and formulation teams supports complex molecules and improves development outcomes • The long-term vision for SmaBioLabs, including commercial manufacturing expansion and becoming a complete end-to-end partner for sponsors If you are involved in pharmaceutical manufacturing, biotech growth, CDMO strategy, or drug development leadership, this conversation offers a practical perspective on building scalable scientific partnerships in a rapidly evolving industry. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent LakshmiDevi Ethirajan Co-Founder & CEO of SmaBioLabs LinkedIn: https://www.linkedin.com/in/lakshmidevi-ethirajan/ Harry Sloan BD CDMO Lead at ARTO LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction 00:14 LakshmiDevi Ethirajan’s journey into pharmaceuticals 01:07 Why sponsor and CDMO alignment matters 02:27 Building an end-to-end CDMO model 03:58 Speed and flexibility in drug development 05:00 Supporting complex molecules through integration 06:46 The meaning behind the SmaBio Labs name 07:56 Growth plans and commercial manufacturing ambitions 08:51 Standing out in the competitive CDMO market 10:17 The North Carolina biotech ecosystem 12:37 Leadership, culture, and patient impact 13:53 Closing remarks #MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #DrugDevelopment #Biotech #LifeSciences #ManufacturingLeadership #PharmaIndustry #Biotechnology #DrugDiscovery #AnalyticalServices #FormulationDevelopment Hosted on Acast. See acast.com/privacy for more information.

    14 Min.
  5. Why Development-Led CDMOs Will Win

    20. Mai

    Why Development-Led CDMOs Will Win

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. How do leading CDMOs move beyond manufacturing to become true development partners? In this episode, Jeffrey Speicher shares how integrated development, technical problem solving and long-term partnerships are shaping growth in outsourced pharma manufacturing. This week on Making It In Manufacturing, Harry Sloan sat down with Jeffrey Speicher, General Manager Commercial of PLD Pharma, with over 30 years of experience spanning engineering, commercial leadership, contract manufacturing, OTC product development and strategic growth across the pharmaceutical and consumer healthcare sectors. In this episode, Jeffrey Speicher covers: - How PLDevelopments evolved from a private label manufacturer into a full CDMO model focused on end-to-end support for customers - Why in-house development and commercialisation capabilities help accelerate speed to market and reduce manufacturing risk for pharmaceutical products - The importance of designing formulations around commercial manufacturing equipment from the very beginning of the R&D process - How product diversification across liquids, tablets, electrolytes, and gummies creates broader manufacturing capabilities within the CDMO market - Why partnership-led relationships matter for pharmaceutical brands looking for quality, consistency, and long-term manufacturing support in the US market For anyone operating across CDMO strategy, OTC innovation or outsourced development, this is a thoughtful conversation on what partnership-led manufacturing really looks like. Be sure to check out the full episode for a deeper discussion on leadership, commercial growth and differentiated execution in pharma services. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Jeffrey Speicher General Manager Commercial at PLD Pharma LinkedIn: https://www.linkedin.com/in/jeffrey-speicher-826746/ Harry Sloan CDMO BD Lead at ARTO LinkedIn: https://www.linkedin.com/in/harry-sloan/ Timestamps: 00:00 Introduction 00:21 Jeffrey Speicher introduction and overview of PL Developments 00:45 The origins of PL Developments and private label manufacturing 01:07 Transitioning into a CDMO-focused business model 01:25 What differentiates PL Developments from traditional CDMOs 01:44 The advantages of broad formulation and manufacturing capabilities 02:26 Why upstream development support improves project success 03:05 Connecting R&D with commercial manufacturing equipment 03:37 Speed to market and reducing commercialisation risk 03:55 Competing through partnership and customer focus 04:29 Balancing speed, efficiency, and scalability in manufacturing 05:09 Developing OTC gummies and expanding manufacturing capabilities 05:28 Designing products around plant strengths 05:40 Eliminating risk during commercial transfer 05:44 Closing remarks #MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #OTCManufacturing #DrugDevelopment #ContractManufacturing #LifeSciences Hosted on Acast. See acast.com/privacy for more information.

    6 Min.
  6. The CDMO Framework Winning Business for Adare Pharma Solutions

    12. Mai

    The CDMO Framework Winning Business for Adare Pharma Solutions

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. The CDMO landscape is crowded, fragmented, and increasingly complex. What does it take to stand out and lead in such a competitive space? This week on Making It In Manufacturing, Harry Sloan sat down with Tom Sellig, CEO of Adare Pharma Solutions with a long-standing career spanning commercial leadership, pharma services, and executive roles across global organisations including, Procter and Gamble, Covance, Patheon, LabConnect, and Thermo Fisher Scientific. In this episode, Tom Sellig covers: - How Adare Pharma Solutions positions itself as a technology-driven oral solid dose CDMO with global capabilities across North America and Europe - Why having both US and European manufacturing capabilities is critical for business continuity, regulatory navigation, and client needs in today’s geopolitical environment - The key differentiators behind Adare’s success, including technological breadth, flexibility as a mid-sized CDMO, and the ability to support both large-scale and highly specialised projects - Building a deeply embedded client-centric culture, including company-wide alignment and continuous customer feedback integration For leaders navigating the CDMO and broader Life Sciences manufacturing space, this episode offers a grounded perspective on strategy, growth, and execution. Watch the full conversation for a clear view on what sustainable leadership in this sector really looks like. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Tom Sellig CEO at Adare Pharma Services LinkedIn: https://www.linkedin.com/in/tomsellig/ Harry Sloan BD CDMO Lead at ARTO LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction 00:20 Overview of Adare Pharma Solutions 01:05 Importance of global footprint in CDMO services 01:45 Key differentiators in a competitive CDMO market 02:43 Client-centric culture and organisational alignment 03:40 Career journey and leadership development 04:25 Lessons from scaling and acquisitions at Patheon 05:05 The Adare framework and company values 05:57 Future outlook for Adare and the CDMO landscape 07:00 Closing remarks #MakingItInManufacturing #ARTOTalent #CDMO #LifeSciences #PharmaManufacturing #Biopharma #Leadership Hosted on Acast. See acast.com/privacy for more information.

    7 Min.
  7. Inside the Race to Scale ADCs - Ian Glassford

    7. Mai

    Inside the Race to Scale ADCs - Ian Glassford

    What does it take to scale complex biologics manufacturing while keeping speed, quality, and communication aligned? In this episode, Ian Glassford explains how integrated CDMO partnerships are helping biotech companies accelerate ADC and bioconjugate programs from discovery through to commercial manufacturing. This week on Making It In Manufacturing, Harry Sloan sat down with Ian Glassford, VP at Abzena, with more than a decade of experience spanning medicinal chemistry, synthetic chemistry, bioconjugation, biologics manufacturing, and CDMO leadership roles across GSK and Abzena. In this episode, Ian Glassford covers: • How Abzena approaches integrated ADC and bioconjugate manufacturing across discovery, development, and GMP production (00:00) • Why communication and true partnership models are becoming critical for CDMOs supporting fast-moving biotech programs (02:55) • The balance between speed to clinic, process standardisation, and maintaining manufacturing quality in complex biologics (03:37) • Ian’s transition from medicinal chemistry at @GSK into leadership within the bioconjugation and ADC space at Abzena (08:11) • Where the future of ADCs, AOCs, radionuclide conjugates, and commercial manufacturing is heading over the next five years (10:25) For anyone working across biologics manufacturing, ADC development, CDMO partnerships, or complex therapeutics, this conversation offers a practical look at how experienced operators are adapting to increasingly demanding timelines and evolving modalities across the biotech industry. Follow ARTO: LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Ian Glassford: LinkedIn: https://www.linkedin.com/in/ian-glassford-phd-mba-28270529/ Harry Sloan: LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/?skipRedirect=true Timestamps: 00:00 Introduction and live recording from DCAT Week in New York 00:39 Ian Glassford explains Abzena’s role in the ADC and bioconjugate CDMO market 01:25 The biggest operational challenges in ADC and AOC manufacturing 02:43 What biotech clients are really looking for beyond technical expertise 03:37 Managing the balance between speed, quality, and execution 04:53 How integrated CDMO and CRO models improve timelines and supply chain control 06:43 The importance of communication and partnership in complex programs 08:11 Ian’s career journey from medicinal chemistry into bio conjugates 10:00 Transitioning from hands-on science into site leadership 10:25 Where Abzena and the wider ADC market are heading in the next five years 11:51 Adapting CDMO models to support evolving biologics modalities 12:29 Closing thoughts #MakingItInManufacturing #ARTOTalent #Biotech #CDMO #Biologics #ADC #DrugDevelopment #Manufacturing #Pharmaceuticals #Bioconjugates Hosted on Acast. See acast.com/privacy for more information.

    13 Min.
  8. How Samsung Biologics Is Redefining CDMO Partnerships - John Gagliardi

    5. Mai

    How Samsung Biologics Is Redefining CDMO Partnerships - John Gagliardi

    95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. How do leading CDMOs move beyond scale to become true strategic partners? This week on Making It In Manufacturing, Harry Sloan sat down with John Gagliardi, Sales Director, Key Account Management at Samsung Biologics, with 25+ years of experience spanning operations, supply chain, procurement, sourcing and commercial leadership across biopharma, including previous experience at GSK and leadership in CDMO partnerships. In this episode, John Gagliardi covers: - How Samsung Biologics has evolved as a pure-play CDMO, including US expansion and the value of integrated support from clinical development through commercial supply. - Why long-term partnerships in biomanufacturing depend on value creation beyond capacity, from lifecycle management to flexible supply chain strategies. - What credible ADC capability really looks like, including integrated manufacturing, simplified supply chains and how co-located operations can accelerate speed to market. - The strategic importance of the Lilly Gateway Labs collaboration with Eli Lilly, and how incubating early-stage biotech can strengthen the future innovation ecosystem. - Where growth is heading next for Samsung Biologics, from Bio Campus expansion and emerging modalities to scaling quality while maintaining operational agility. If you are interested in where biomanufacturing partnerships are heading, and how leading CDMOs are thinking beyond capacity alone, this conversation offers practical insight worth your time. Watch the full episode to hear how John approaches growth, innovation and patient impact through a commercial and operational lens. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent John Gagliardi Sales Director at Samsung Biologics LinkedIn: https://www.linkedin.com/in/john-gagliardi-7a8a252/ Harry Sloan CDMO BD Lead at ARTO LinkedIn: linkedin.com/in/harry-sloan-605620154/?lipi=urn%3Ali%3Apage%3Ad_flagship3_profile_view_base%3B7ieBaX%2FATH6lSPMIPdsI8w%3D%3D Timestamps: 00:00 Introduction from New York and conference spotlight 00:42 Samsung Biologics as a pure-play CDMO 02:10 Building strategic customer partnerships 03:45 Differentiation beyond standard CDMO models 05:01 Building credibility in ADC manufacturing 07:53 Technical collaboration and winning partnerships 09:07 Lilly Gateway Labs collaboration 11:40 Growth trajectory and future modalities 13:19 Scaling while maintaining quality 15:00 Patient impact and personal motivation 16:35 Closing remarks #MakingItInManufacturing #ARTOTalent #Biomanufacturing #CDMO #Biopharma #SupplyChain #ADC #PharmaceuticalManufacturing #BiotechLeadership Hosted on Acast. See acast.com/privacy for more information.

    17 Min.
Alle anzeigen (36)

Info

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

Informationen

  • Erstellt von
    ARTO Talent
  • Jahre aktiv
    2025 - 2026
  • Folgen
    36
  • Bewertung
    Unbedenklich
  • Copyright
    © ARTO Talent
  • Sendungswebsite
    Making it in Manufacturing